Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Exp Neurol ; 299(Pt A): 109-121, 2018 01.
Article in English | MEDLINE | ID: mdl-29037533

ABSTRACT

No treatment is available for patients with spinal cord injury (SCI). Patients often arrive to the hospital hours after SCI suggesting the need of a therapy that can be used on a clinically relevant window. Previous studies showed that Tamoxifen (TAM) treatment 24h after SCI benefits locomotor recovery in female rats. Tamoxifen exerts beneficial effects in male and female rodents but a gap of knowledge exists on: the therapeutic window of TAM, the spatio-temporal mechanisms activated and if this response is sexually dimorphic. We hypothesized that TAM will favor locomotor recovery when administered up-to 24h after SCI in male Sprague-Dawley rats. Rats received a thoracic (T10) contusion using the MACSIS impactor followed by placebo or TAM (15mg/21days) pellets in a therapeutic window of 0, 6, 12, or 24h. Animals were sacrificed at 2, 7, 14, 28 or 35days post injury (DPI) to study the molecular and cellular changes in the acute and chronic stages. Immediate or delayed therapy (t=6h) improved locomotor function, increased white matter spared tissue, and neuronal survival. TAM reduced reactive gliosis during chronic stages and increased the expression of Olig-2. A significant difference was observed in estrogen receptor alpha between male and female rodents from 2 to 28 DPI suggesting a sexually dimorphic characteristic that could be related to the behavioral differences observed in the therapeutic window of TAM. This study supports the use of TAM in the SCI setting due to its neuroprotective effects but with a significant sexually dimorphic therapeutic window.


Subject(s)
Locomotion , Neuroglia/drug effects , Neurons/drug effects , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/therapeutic use , Spinal Cord Injuries/drug therapy , Tamoxifen/administration & dosage , Tamoxifen/therapeutic use , Animals , Behavior, Animal , Estrogen Receptor alpha/metabolism , Female , Glial Fibrillary Acidic Protein/biosynthesis , Glial Fibrillary Acidic Protein/genetics , Gliosis/pathology , Male , Oligodendrocyte Transcription Factor 2/biosynthesis , Oligodendrocyte Transcription Factor 2/genetics , Rats , Rats, Sprague-Dawley , Recovery of Function , Sex Characteristics , Time-to-Treatment
2.
J Neurotrauma ; 33(18): 1696-708, 2016 09 15.
Article in English | MEDLINE | ID: mdl-26896212

ABSTRACT

Spinal cord injury (SCI) is a condition with no available cure. The initial physical impact triggers a cascade of molecular and cellular events that generate a nonpermissive environment for cell survival and axonal regeneration. Spinal cord injured patients often arrive at the clinic hours after the initial insult. This indicates the need to study and develop treatments with a long therapeutic window of action and multiactive properties, which target the complex set of events that arise after the initial trauma. We provide evidence that tamoxifen (TAM), a drug approved by the Food and Drug Administration, exerts neuroprotective effects in an animal model when applied up-to 24 h after SCI. We hypothesized that continuous TAM administration will improve functional locomotor recovery by favoring myelin preservation and reducing secondary damage after SCI. Adult female Sprague-Dawley rats (∼230 g) received a moderate contusion to the thoracic (T9-T10) spinal cord, using the MASCIS impactor device. To determine the therapeutic window available for TAM treatment, rats were implanted with TAM pellets (15 mg) immediately or 24 h after SCI. Locomotor function (Basso, Beattie, Bresnahan open field test, grid walk, and beam crossing tests) was assessed weekly for 35 days post-injury. TAM-treated rats showed significant functional locomotor recovery and improved fine movements when treated immediately or 24 h after SCI. Further, TAM increased white matter preservation and reduced secondary damage caused by astrogliosis, axonal degeneration, and cell death after trauma. These results provide evidence for TAM as a potential therapeutic agent to treat SCI up to 24 h after the trauma.


Subject(s)
Locomotion/drug effects , Neuroprotective Agents/pharmacology , Recovery of Function/drug effects , Spinal Cord Injuries/complications , Tamoxifen/pharmacology , Animals , Female , Rats , Rats, Sprague-Dawley , Spinal Cord Injuries/pathology
3.
Neural Regen Res ; 10(3): 385-90, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25878585

ABSTRACT

Spinal cord injury (SCI) is a devastating condition that produces significant changes in the lifestyle of patients. Many molecular and cellular events are triggered after the initial physical impact to the cord. Two major phases have been described in the field of SCI: an acute phase and late phase. Most of the therapeutic strategies are focused on the late phase because this provides an opportunity to target cellular events like apoptosis, demyelination, scar formation and axonal outgrowth. In this mini-review, we will focus on two agents (tamoxifen and a Src kinase family inhibitor known as PP2) that have been shown in our laboratory to produce neuroprotective (increase cell survival) and/or regenerative (axonal outgrowth) actions. The animal model used in our laboratory is adult female rat (~250 g) with a moderate contusion (12.5 mm) to the spinal cord at the T10 level, using the MASCIS impactor device. Tamoxifen or PP2 was administered by implantation of a 15 mg pellet (Innovative Research of America, Sarasota, FL, USA) or by intraperitoneal injections (1.5 mg/kg, every 3 days), respectively, to produce a long-term effect (28 days). Tamoxifen and the Src kinase inhibitor, PP2, are drugs that in rats with a moderate spinal cord injury promote functional locomotor recovery, increase spared white matter tissue, and stimulate axonal outgrowth. Moreover, tamoxifen reduces the formation of reactive oxygen species. Therefore, these drugs are possible therapeutic agents that have a neuroprotective/regenerative activity in vertebrates with SCI.

4.
J Vet Sci Technol ; 6(6): 276, 2015 Nov 30.
Article in English | MEDLINE | ID: mdl-26962471

ABSTRACT

Fluctuating sex steroids during the estrous or menstrual cycle of mammalian females make it difficult to determine their role on behaviors and physiology. To avoid this, many investigators ovariectomize their animals and administer progesterone, estradiol or a combination of both. Several different strategies are used to administer estradiol, which confounds interpretation of results. This study compared two methods of estradiol replacement implants: Silastic tubes filled with crystalline estradiol benzoate (E2) and commercially available estradiol benzoate pellets. Implants were placed subcutaneously in adult ovariectomized (OVX) rats and blood samples obtained weekly. Control OVX rats received empty Silastic tubes or placebo pellets. Our data shows that E2 plasma levels from rats with Silastic implants peaked after one week and decreased slowly thereafter. In contrast, plasma E2 from commercial pellets peaked after two weeks, increasing and decreasing over time. To validate hormone release, body weight was monitored. All E2 treated animals maintained a similar body weight over the four weeks period whereas an increase in body weight over time was observed in the OVX group that received empty implants, confirming E2 release and supporting the role of E2 in the regulation of body weight. Furthermore, the effects of E2 on basal locomotor activity were assessed using animal activity cages. Results showed no difference between E2 and control group in several locomotor activities. These results indicate that Silastic implants achieve more stable plasma estradiol levels than pellets and thus are a better alternative for studies of estradiol on brain function and behavior.

5.
Brain Res ; 1561: 11-22, 2014 May 02.
Article in English | MEDLINE | ID: mdl-24637260

ABSTRACT

17ß-Estradiol is a multi-active steroid that imparts neuroprotection via diverse mechanisms of action. However, its role as a neuroprotective agent after spinal cord injury (SCI), or the involvement of the estrogen receptor-alpha (ER-α) in locomotor recovery, is still a subject of much debate. In this study, we evaluated the effects of estradiol and of Tamoxifen (an estrogen receptor mixed agonist/antagonist) on locomotor recovery following SCI. To control estradiol cyclical variability, ovariectomized female rats received empty or estradiol filled implants, prior to a moderate contusion to the spinal cord. Estradiol improved locomotor function at 7, 14, 21, and 28 days post injury (DPI), when compared to control groups (measured with the BBB open field test). This effect was ER-α mediated, because functional recovery was blocked with an ER-α antagonist. We also observed that ER-α was up-regulated after SCI. Long-term treatment (28 DPI) with estradiol and Tamoxifen reduced the extent of the lesion cavity, an effect also mediated by ER-α. The antioxidant effects of estradiol were seen acutely at 2 DPI but not at 28 DPI, and this acute effect was not receptor mediated. Rats treated with Tamoxifen recovered some locomotor activity at 21 and 28 DPI, which could be related to the antioxidant protection seen at these time points. These results show that estradiol improves functional outcome, and these protective effects are mediated by the ER-α dependent and independent-mechanisms. Tamoxifen׳s effects during late stages of SCI support the use of this drug as a long-term alternative treatment for this condition.


Subject(s)
Antioxidants/pharmacology , Estradiol/pharmacology , Neuroprotective Agents/pharmacology , Spinal Cord Injuries/drug therapy , Tamoxifen/pharmacology , Animals , Drug Implants , Estrogen Antagonists/pharmacology , Estrogen Receptor Modulators/blood , Estrogen Receptor Modulators/pharmacology , Estrogen Receptor alpha/antagonists & inhibitors , Estrogen Receptor alpha/metabolism , Female , Motor Activity/drug effects , Motor Activity/physiology , Nerve Fibers, Myelinated/drug effects , Nerve Fibers, Myelinated/pathology , Nerve Fibers, Myelinated/physiology , Oxidative Stress/drug effects , Oxidative Stress/physiology , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Recovery of Function/drug effects , Recovery of Function/physiology , Spinal Cord/drug effects , Spinal Cord/pathology , Spinal Cord Injuries/pathology , Spinal Cord Injuries/physiopathology , Tamoxifen/blood , Time Factors
6.
Neural Regen Res ; 9(24): 2164-73, 2014 Dec 15.
Article in English | MEDLINE | ID: mdl-25657738

ABSTRACT

The spinal cord has the ability to regenerate but the microenvironment generated after trauma reduces that capacity. An increase in Src family kinase (SFK) activity has been implicated in neuropathological conditions associated with central nervous system trauma. Therefore, we hypothesized that a decrease in SFK activation by a long-term treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine (PP2), a selective SFK inhibitor, after spinal cord contusion with the New York University (NYU) impactor device would generate a permissive environment that improves axonal sprouting and/or behavioral activity. Results demonstrated that long-term blockade of SFK activation with PP2 increases locomotor activity at 7, 14, 21 and 28 days post-injury in the Basso, Beattie, and Bresnahan open field test, round and square beam crossing tests. In addition, an increase in white matter spared tissue and serotonin fiber density was observed in animals treated with PP2. However, blockade of SFK activity did not change the astrocytic response or infiltration of cells from the immune system at 28 days post-injury. Moreover, a reduced SFK activity with PP2 diminished Ephexin (a guanine nucleotide exchange factor) phosphorylation in the acute phase (4 days post-injury) after trauma. Together, these findings suggest a potential role of SFK in the regulation of spared tissue and/or axonal outgrowth that may result in functional locomotor recovery during the pathophysiology generated after spinal cord injury. Our study also points out that ephexin1 phosphorylation (activation) by SFK action may be involved in the repulsive microenvironment generated after spinal cord injury.

7.
J Mol Neurosci ; 49(2): 347-59, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22878913

ABSTRACT

Some receptors that block axonal regeneration or promote cell death after spinal cord injury (SCI) are localized in membrane rafts. Flotillin-2 (Flot-2) is an essential protein associated with the formation of these domains and the clustering of membranal proteins, which may have signaling activities. Our hypothesis is that trauma will change Flot-2 expression and interference of this lipid raft marker will promote functional locomotor recovery after SCI. Analyses were conducted to determine the spatiotemporal profile of Flot-2 expression in adult rats after SCI, using the MASCIS impactor device. Immunoblots showed that SCI produced a significant decrease in the level of Flot-2 at 2 days post-injury (DPI) that increased until 28 DPI. Confocal microscopy revealed Flot-2 expression in neurons, reactive astrocytes and oligodendrocytes specifically associated to myelin structures near or close to the axons of the cord. In the open field test and grid walking assays, to monitor locomotor recovery of injured rats infused intrathecally with Flot-2 antisense oligonucleotides for 28 days showed significant behavioral improvement at 14, 21 and 28 DPI. These findings suggest that Flot-2 has a role in the nonpermissive environment that blocks locomotor recovery after SCI by clustering unfavorable proteins in membrane rafts.


Subject(s)
Membrane Proteins/metabolism , Spinal Cord Injuries/metabolism , Animals , Astrocytes/metabolism , Female , Gene Expression , Membrane Microdomains/metabolism , Membrane Proteins/genetics , Motor Activity , Myelin Sheath/metabolism , Neurons/metabolism , Rats , Rats, Sprague-Dawley , Spinal Cord/cytology , Spinal Cord/metabolism , Spinal Cord Injuries/physiopathology
8.
J Neurotrauma ; 29(3): 551-66, 2012 Feb 10.
Article in English | MEDLINE | ID: mdl-21970623

ABSTRACT

Currently, few interventions have been shown to successfully limit the progression of secondary damage events associated with the acute phase of spinal cord injury (SCI). Docosahexaenoic acid (DHA, C22:6 n-3) is neuroprotective when administered following SCI, but its potential as a pretreatment modality has not been addressed. This study used a novel DHA pretreatment experimental paradigm that targets acute cellular and molecular events during the first week after SCI in rats. We found that DHA pretreatment reduced functional deficits during the acute phase of injury, as shown by significant improvements in Basso-Beattie-Bresnahan (BBB) locomotor scores, and the detection of transcranial magnetic motor evoked potentials (tcMMEPs) compared to vehicle-pretreated animals. We demonstrated that, at 7 days post-injury, DHA pretreatment significantly increased the percentage of white matter sparing, and resulted in axonal preservation, compared to the vehicle injections. We found a significant increase in the survival of NG2+, APC+, and NeuN+ cells in the ventrolateral funiculus (VLF), dorsal corticospinal tract (dCST), and ventral horns, respectively. Interestingly, these DHA protective effects were observed despite the lack of inhibition of inflammatory markers for monocytes/macrophages and astrocytes, ED1/OX42 and GFAP, respectively. DHA pretreatment induced levels of Akt and cyclic AMP responsive element binding protein (CREB) mRNA and protein. This study shows for the first time that DHA pretreatment ameliorates functional deficits, and increases tissue sparing and precursor cell survival. Further, our data suggest that DHA-mediated activation of pro-survival/anti-apoptotic pathways may be independent of its anti-inflammatory effects.


Subject(s)
Docosahexaenoic Acids/pharmacology , Neuroprotective Agents , Spinal Cord Injuries/prevention & control , Animals , Cell Death/drug effects , Cyclic AMP Response Element-Binding Protein/physiology , Evoked Potentials, Motor/drug effects , Female , Fluorescent Antibody Technique , Hindlimb/physiology , In Situ Nick-End Labeling , Inflammation/pathology , Injections, Intravenous , Locomotion/physiology , Macrophage Activation/drug effects , Microglia/drug effects , Myelin Sheath/metabolism , Myelin Sheath/pathology , Neural Conduction/drug effects , Neural Stem Cells/drug effects , Oncogene Protein v-akt/metabolism , Rats , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Signal Transduction/drug effects , Spinal Cord Injuries/pathology
9.
J Mol Neurosci ; 46(1): 167-76, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21647706

ABSTRACT

Spinal cord injury (SCI) triggers a sequel of events commonly associated with cell death and dysfunction of glias and neurons surrounding the lesion. Although astrogliosis and glial scar formation have been involved in both damage and repair processes after SCI, their role remains controversial. Our goal was to investigate the effects of the P2 receptors antagonists, PPADS and suramin, in the establishment of the reactive gliosis and the formation of the glial scar. Molecular biology, immunohistochemistry, spared tissue, and locomotor behavioral studies were used to evaluate astrogliosis, in adult female Sprague-Dawley rats treated with P2 antagonists after moderate injury with the NYU impactor device. Semi-quantitative RT-PCR confirmed the presence of P2Y(1,) P2Y(2,) P2Y(4,) P2Y(6,) P2Y(12), and P2X(2) receptors in the adult spinal cord. Immunohistochemistry studies confirmed a significant decrease in GFAP-labeled cells at the injury epicenter as well as a decrease in spared tissue after treatment with the antagonists. Functional open field testing revealed no significant locomotor score differences between treated and control animals. Our work is consistent with studies suggesting that astrogliosis is an important event after SCI that limits tissue damage and lesion spreading.


Subject(s)
Gliosis/drug therapy , Purinergic P2 Receptor Antagonists/pharmacology , Pyridoxal Phosphate/analogs & derivatives , Spinal Cord Injuries/drug therapy , Spinal Cord/pathology , Suramin/pharmacology , Animals , Antineoplastic Agents/pharmacology , Astrocytes/drug effects , Astrocytes/metabolism , Behavior, Animal/drug effects , Behavior, Animal/physiology , Female , Glial Fibrillary Acidic Protein/metabolism , Gliosis/pathology , Motor Activity/drug effects , Motor Activity/physiology , Platelet Aggregation Inhibitors/pharmacology , Pyridoxal Phosphate/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Purinergic P2/genetics , Recovery of Function/drug effects , Recovery of Function/physiology , Spinal Cord Injuries/pathology
10.
Cell Mol Neurobiol ; 31(7): 1057-69, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21603973

ABSTRACT

Spinal cord injury (SCI) triggers the re-expression of inhibitory molecules present in early stages of development, contributing to prevention of axonal regeneration. Upregulation of EphA receptor tyrosine kinases after injury suggest their involvement in the nervous system's response to damage. However, the expression profile of their ephrinA ligands after SCI is unclear. In this study, we determined the expression of ephrinA ligands after contusive SCI. Adult Sprague-Dawley female rats were injured using the MASCIS impactor device at the T10 vertebrae, and levels of ephrinA mRNA and protein determined at different time points. Identification of the cell phenotype expressing the ephrin ligand and colocalization with Eph receptors was performed with immunohistochemistry and confocal microscopy. Behavioral studies were made, after blocking ephrinA1 expression with antisense (AS) oligonucleotides, to assess hindlimb locomotor activity. Real-time PCR demonstrated basal mRNA levels of ephrin (A1, A2, A3, and A5) in the adult spinal cord. Interestingly, ephrinA1 was the only ligand whose mRNA levels were significantly altered after SCI. Although ephrinA1 mRNA levels increased after 2 weeks and remain elevated, we did not observe this pattern at the protein level as revealed by western blot analysis. Immunohistochemical studies showed ephrinA1 expression in reactive astrocytes, axons, and neurons and also their colocalization with EphA4 and A7 receptors. Behavioral studies revealed worsening of locomotor activity when ephrinA1 expression was reduced. This study suggests that ephrinA1 ligands play a role in the pathophysiology of SCI.


Subject(s)
Ephrin-A1/metabolism , Ligands , Spinal Cord Injuries/physiopathology , Animals , Ephrin-A1/genetics , Female , Gene Expression Profiling , Motor Activity/physiology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Eph Family/metabolism , Spinal Cord/cytology , Spinal Cord/metabolism , Spinal Cord/pathology
11.
Dev Neurobiol ; 71(7): 595-607, 2011 Jul.
Article in English | MEDLINE | ID: mdl-20949525

ABSTRACT

Failure of axon regeneration after traumatic spinal cord injury (SCI) is attributable in part to the presence of inhibitory molecular interactions. Recent evidence demonstrates that activation of Eph signaling pathways leads to modulation of growth cone dynamics and repulsion through the activation of ephexin, a novel guanine nucleotide exchange factor (GEF). However, little is known about the expression and modulation of Eph molecular targets in the injured spinal cord. In this study, we determined the expression profile of ephexin after a moderate spinal cord contusion at thoracic level (T10) in young adult rats. Western-blot studies showed increased protein expression in injured rats at 4 and 7 days postinjury (DPI) when compared with control animals. The protein levels returned to normal at 14 DPI and remained steady until 28 DPI. However, immunoprecipitation studies of the phosphorylated ephexin demonstrated that this protein is activated by day 2 until 14 DPI. Expression of ephexin was noticeable in neurons, axons, microglia/macrophages, and reactive astrocytes, and co-localized with EphA3, A4, and A7. These results demonstrate the presence of ephexin in the adult spinal cord and its activation after SCI. Therefore, we show, for the first time, the spatiotemporal pattern of ephexin expression and activation after contusive SCI. Collectively, our data support our previous findings on the putative nonpermissive roles of Eph receptors after SCI and the possible involvement of ephexin in the intracellular cascade of events.


Subject(s)
Guanine Nucleotide Exchange Factors/metabolism , Spinal Cord Injuries/metabolism , Animals , Blotting, Western , Enzyme Activation , Female , Gene Expression , Gene Expression Profiling , Immunohistochemistry , Immunoprecipitation , Rats , Rats, Sprague-Dawley
12.
Int J Dev Neurosci ; 28(6): 413-21, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20619335

ABSTRACT

Spinal cord injury increases inhibitory factors that may restrict neurite outgrowth after trauma. The expression of repulsive molecules in reactive astrocytes and the formation of the glial scar at the injury site produce the non-permissive environment for axonal regeneration. However, the mechanism that triggers this astrogliotic response is unknown. The release of nucleotides has been linked to this hypertrophic state. Our goal is to investigate the temporal profile of P2Y(2) nucleotide receptor after spinal cord injury in adult female Sprague-Dawley rats. Molecular biology, immunofluorescence studies, and Western Blots were used to evaluate the temporal profile (2, 4, 7, 14, and 28 days post-injury) of this receptor in rats injured at the T-10 level using the NYU impactor device. Real time RT-PCR showed a significant increase of P2Y(2) mRNA after 2 days post-injury that continues throughout 28 days post-injury. Double labeling studies localized P2Y(2) immunoreactivity in neuronal cell bodies, axons, macrophages, oligodendrocytes and reactive astrocytes. Immunofluorescence studies also demonstrated a low level of P2Y(2) receptor in sham samples, which increased after injury in glial fibrillary acidic protein positive cells. Western Blot performed with contused spinal cord protein samples revealed an upregulation in the P2Y(2) 42 kDa protein band expression after 4 days post-injury that continues until 28 days post-injury. However, a downregulation of the 62 kDa receptor protein band after 2 days post-injury that continues up to 28 days post-injury was observed. Therefore, the spatio-temporal pattern of P2Y(2) gene expression after spinal cord injury suggests a role in the pathophysiology response generated after trauma.


Subject(s)
Receptors, Purinergic P2Y2/metabolism , Spinal Cord Injuries/metabolism , Spinal Cord/metabolism , Animals , Female , Gene Expression Regulation , Rats , Rats, Sprague-Dawley , Thoracic Vertebrae , Tissue Distribution
13.
J Neurotrauma ; 26(10): 1783-93, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19653810

ABSTRACT

Acute pain is a common symptom experienced after spinal cord injury (SCI). The presence of this pain calls for treatment with analgesics, such as buprenorphine. However, there are concerns that the drug may exert other effects besides alleviation of pain. Among those reported are in vitro changes in gene expression, apoptosis, and necrosis. In this investigation, the effect of buprenorphine was assessed at the molecular, behavioral, electrophysiological, and histological levels after SCI. Rats were injured at the T10 thoracic level using the NYU impactor device. Half of the animals received buprenorphine (0.05 mg/kg) for 3 consecutive days immediately after SCI, and the other half were untreated. Microarray analysis (n = 5) was performed and analyzed using the Array Assist software. The genes under study were grouped in four categories according to function: regeneration, apoptosis, second messengers, and nociceptive related genes. Microarray analysis demonstrated no significant difference in gene expression between rats treated with buprenorphine and the control group at 2 and 4 days post-injury (DPI). Experiments performed to determine the effect of buprenorphine at the electrophysiological (tcMMEP), behavioral (BBB, grid walking and beam crossing), and histological (luxol staining) levels revealed no significant difference at 7 and 14 DPI in the return of nerve conduction, functional recovery, or white matter sparing between control and experimental groups (p > 0.05, n = 6). These results show that buprenorphine (0.05 mg/kg) can be used as part of the postoperative care to reduce pain after SCI without affecting behavioral, physiological, or anatomical parameters.


Subject(s)
Analgesics, Opioid/pharmacology , Buprenorphine/pharmacology , Gene Expression Regulation/drug effects , Pain, Intractable/drug therapy , Pain, Intractable/etiology , Recovery of Function/drug effects , Spinal Cord Injuries/complications , Analgesics, Opioid/adverse effects , Animals , Apoptosis/drug effects , Apoptosis/genetics , Buprenorphine/adverse effects , Disease Models, Animal , Evoked Potentials, Motor/drug effects , Evoked Potentials, Motor/physiology , Female , Gait Disorders, Neurologic/chemically induced , Gait Disorders, Neurologic/physiopathology , Gene Expression Regulation/physiology , Locomotion/drug effects , Locomotion/physiology , Nerve Regeneration/drug effects , Nerve Regeneration/genetics , Nerve Tissue Proteins/genetics , Neural Conduction/drug effects , Neural Conduction/physiology , Nociceptors/drug effects , Nociceptors/metabolism , Oligonucleotide Array Sequence Analysis , Pain, Intractable/metabolism , Rats , Rats, Sprague-Dawley , Recovery of Function/physiology , Second Messenger Systems/drug effects , Second Messenger Systems/genetics , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/physiopathology , Treatment Outcome
14.
J Neurosci Res ; 84(7): 1438-51, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-16983667

ABSTRACT

Functional impairment after spinal cord injury (SCI) is partially attributed to neuronal cell death, with further degeneration caused by the accompanying apoptosis of myelin-forming oligodendrocytes. The Eph receptor protein tyrosine kinase family and its cognate ligands, the ephrins, have been identified to be involved in axonal outgrowth, synapse formation, and target recognition, mainly mediated by repulsive activity. Recent reports suggest that ephrin/Eph signaling might also play a role as a physiological trigger for apoptosis during embryonic development. Here, we investigated the expression profile of EphA7, after SCI, by using a combination of quantitative real-time PCR (QRT-PCR) and immunohistochemical techniques. QRT-PCR analysis showed an increase in the expression of full-length EphA7 at 7 days postinjury (DPI). Receptor immunoreactivity was shown mostly in astrocytes of the white matter at the injury epicenter. In control animals, EphA7 expression was observed predominantly in motor neurons of the ventral gray matter, although some immunoreactivity was seen in white matter. Furthermore, blocking the expression of EphA7 after SCI using antisense oligonucleotides resulted in significant acceleration of hindlimb locomotor recovery at 1 week. This was a transient effect; by 2 weeks postinjury, treated animals were not different from controls. Antisense treatment also produced a return of nerve conduction, with shorter latencies than in control treated animals after transcranial magnetic stimulation. We identified EphA7 receptors as putative regulators of apoptosis in the acute phase after SCI. These results suggest a functional role for EphA7 receptors in the early stages of SCI pathophysiology.


Subject(s)
Apoptosis/physiology , Motor Activity/physiology , Receptor, EphA7/metabolism , Recovery of Function/physiology , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/physiopathology , Analysis of Variance , Animals , Apoptosis/drug effects , Astrocytes/metabolism , Female , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry/methods , In Situ Nick-End Labeling/methods , Membrane Potentials/drug effects , Membrane Potentials/physiology , Motor Activity/drug effects , Oligodeoxyribonucleotides, Antisense/pharmacology , Patch-Clamp Techniques/methods , Phosphopyruvate Hydratase/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Receptor, EphA7/antagonists & inhibitors , Receptor, EphA7/genetics , Recovery of Function/drug effects , Reverse Transcriptase Polymerase Chain Reaction/methods , Spinal Cord Injuries/drug therapy , Spinal Cord Injuries/pathology , Time Factors , Up-Regulation/drug effects , Up-Regulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...